Table 1.

Factors associated with reduced susceptibility to ciprofloxacin in 26,081 isolates of S. pneumoniae collected between 1998 and 2009 by the Canadian Bacterial Surveillance Network^a

Factorb	No. (%) of isolates with a ciprofloxacin MIC ≥ 4 μg/ml	P valuec
Geographic aread		0.002
Central Canada	415/18,981 (2.2)
Eastern Canada	64/3,265 (2.0)
Western Canada	50/3,725 (1.3)
Patient age		<0.001
<15 yrs	17/6,524 (0.26)
15–64 yrs	173/10,253 (1.7)
>64 yrs	336/8,720 (3.9)
Source of isolate		<0.001
Blood or other sterile fluid	106/10,080 (1.0)
Respiratory tract, nonsterile	389/10,450 (3.7)
Other	32/5,410 (0.59)
Type of laboratorye		<0.001
Community	53/4,149 (1.3)
Hospital, <200 beds	12/922 (1.3)
Hospital, 200–499 beds	172/9,013 (1.9)
Hospital, 500–699 beds	93/4,125 (2.3%)
Hospital, ≥700 beds	193/6,936 (2.8%)
Penicillin MIC of isolate		<0.001
<0.125 μg/ml	396/21,876 (1.8)
0.125–1 μg/ml	64/2,391 (2.7)
>1 μg/ml	85/1,787 (5.3)

^aData shown are for reduced susceptibility to ciprofloxacin (MIC ≥ 4 μg/ml); analysis of factors associated with levofloxacin and moxifloxacin yielded indistinguishable results.

^bThe submitting center (geographic area) was missing for 2 (<.1%) isolates, the patient's age was unknown for 302 (1.1%) specimens, and the type of specimen (source) was unknown for 32 (0.12%) isolates.

^cLikelihood ratio chi-square test.

^dCentral Canada includes the provinces of Manitoba, Ontario, and Quebec; eastern Canada includes the Atlantic provinces; western Canada includes Saskatchewan, Alberta, British Columbia, the Yukon, and the Northwest Territories.

^eA total of 936 isolates were submitted from laboratories that service hospitals of various sizes.